Beone Medicines Ltd. delivered a strong second-quarter performance, with its core commercial products continuing to expand. The company's revenue, profits, and cash flow all improved simultaneously, demonstrating the onset of economies of scale.
According to the financial results released on August 5, the company's total global revenue for the second quarter reached $1.7 billion, a 30% increase year-over-year. For the first half of the year, cumulative revenue exceeded $3.2 billion, up 32% compared to the same period last year. The profit side was even more impressive: GAAP operating profit for the second quarter was $325 million, a 270% surge, while GAAP net profit hit $237 million, soaring 151%. On a non-GAAP adjusted basis, net profit was $444 million, a 76% increase.
On the cash flow front, the company generated $435 million in free cash flow during the second quarter, nearly doubling from the prior year. Free cash flow for the first half of the year reached $596 million, a 187% increase. As of the end of the second quarter, the company held $5.28 billion in cash and cash equivalents, an increase of approximately $670 million from the start of the year.
Driven by this strong performance, Beone Medicines simultaneously raised its full-year guidance. The company now expects total revenue for fiscal 2026 to be between $6.6 billion and $6.8 billion, exceeding previous forecasts. GAAP operating profit guidance has been raised to $1.0 billion to $1.1 billion, while non-GAAP operating profit guidance is now set at $1.7 billion to $1.8 billion.
Zanubrutinib Sales Surpass $1.2 Billion, Becoming the Core Growth Driver
The core product, Brukinsa (zanubrutinib), continued to be the primary growth engine. In the second quarter, zanubrutinib's global sales reached $1.2 billion, a 31% increase year-over-year. Sales in the U.S. market specifically were $893 million, also up 31%. As its market share continues to rise, this product has become the central pillar for revenue growth and profit improvement.
Other commercialized products also maintained growth. Global sales of Baizean (tislelizumab) reached $229 million in the second quarter, an 18% increase. Sales of Amgen-licensed products worldwide were $157 million, up 25%.
This product mix optimization also boosted profitability. The company's GAAP gross margin for the second quarter improved to 90%, up 3 percentage points from the same period last year, primarily benefiting from a higher proportion of zanubrutinib sales and improved production efficiency.
Revenue Growth Outpaces Expense Growth, Releasing Operating Leverage
As commercial scale expands, Beone Medicines' expense growth has become more rational. Total operating expenses for the second quarter were $1.205 billion, a 13% increase year-over-year, which was lower than the 30% revenue growth rate, further demonstrating economies of scale.
Research and development (R&D) expenses, calculated on a GAAP basis, were $612 million, a 17% increase, primarily due to the advancement of late-stage clinical programs and an increase in upfront payments and milestone payments related to in-licensed assets. These related expenses reached $23.3 million, compared to just $0.5 million in the same period last year.
Selling, general, and administrative (SG&A) expenses were $593 million, a 10% increase, but their proportion of product revenue decreased to 35% from 41% in the same period last year, indicating a continuous improvement in commercial efficiency.
Pipeline Enters Harvest Phase with Multiple Key Data and Regulatory Milestones Ahead
Beyond the growth of commercial products, Beone Medicines' R&D pipeline has also achieved several important milestones. For zanubrutinib, the company announced positive results from the Phase 3 MANGROVE study, showing a significant progression-free survival (PFS) benefit when combined with rituximab in treatment-naïve mantle cell lymphoma (MCL) patients. Additionally, long-term follow-up data from the SEQUOIA study at 78 months further strengthened the evidence of long-term benefit in chronic lymphocytic leukemia (CLL).
Brukinsa (sotorasib) received accelerated approval from the U.S. FDA for adult patients with relapsed/refractory MCL who have received at least two prior lines of therapy, including a BTK inhibitor, further completing the hematologic oncology product portfolio.
For Baizean, the company received approval in Japan for the first-line treatment of gastric cancer. Data from the Phase 3 HERIZON-GEA-01 study of Bahe'an (zenocutuzumab) was also published in the New England Journal of Medicine, evaluating its potential in the first-line treatment of HER2-positive gastroesophageal adenocarcinoma.
Furthermore, the company is advancing its solid tumor pipeline and disclosed proof-of-concept data for three candidate products: the CDK4 inhibitor BGB-43395, the GPC3×4-1BB bispecific antibody BGB-B2033, and the B7-H4 ADC BG-C9074.
Investing in U.S. Manufacturing Capacity to Strengthen Global Presence
In terms of industrial layout, Beone Medicines announced an additional $300 million investment to expand its flagship manufacturing and R&D center in New Jersey, USA. This expansion will add small molecule drug production capabilities to further strengthen its global supply chain.
Concurrently, the company completed a board reshuffle, appointing three new directors: Dr. Felix J. Baker, Ms. Elizabeth F. Mooney, and Dr. Charles L. Sawyers, to further refine its governance structure.
Additionally, the company stated that, with improving profitability, the 2026 performance could provide a basis for reversing some valuation allowances, potentially generating tax benefits. However, the timing and scale of this matter remain uncertain.
Overall, Beone Medicines' second-quarter results show that the company is transitioning from a high-investment period to a phase of commercial realization. The continued expansion of zanubrutinib sales, improved expense efficiency, and the pipeline's entry into key milestones are collectively driving the company's profitability onto an upward trajectory.
Comments